| pubmed-article:2167645 | pubmed:abstractText | The efficacy of concentrated CDDP-Lipiodol Emulsion was experimentally and clinically studied in the treatment of nonresectable hepatoma. The commercially available CDDP was ten-fold concentrated into water in oil form. The agent was administered via hepatic artery in 26 patients with nonresectable hepatocellular carcinoma. In vitro and clinical studies strongly suggested a gradual release of the CDDP into the surrounding tissue. In 9 out of 26 patients (34.6%), tumor regression was found. Side effects were minimum; mild nausea and vomiting were observed in only 13 patients. On the basis of our preliminary study, concentrated CDDP-Lipiodol emulsion promises to be a useful agent for the treatment of nonresectable hepatocellular carcinoma. | lld:pubmed |
